HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $66 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $66 price target.
June 28, 2024 | 5:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Mirum Pharmaceuticals and maintained a $66 price target.
The reiteration of a Buy rating and the maintenance of a $66 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100